Rhelion Subsidiary Filament Health Ships PEX010 to USC for Psychedelic Therapy Trial

PUBT · 2d ago
Rhelion Subsidiary Filament Health Ships PEX010 to USC for Psychedelic Therapy Trial
  • Rhelion Life Sciences' wholly owned subsidiary Filament Health shipped PEX010 to the University of Southern California for a psychedelic therapy trial.
  • The shipment is the first under the supply and licensing agreement announced September 15, 2026.
  • The USC-sponsored Mindfulness Assisted Psychedelic Therapy trial will evaluate whether mindfulness and meditation training can augment psilocybin-assisted therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611030802NEWSFILECNPR____20261103_322278_1) on November 03, 2026, and is solely responsible for the information contained therein.